Collaborative Networks Driving Regulatory Transformation in Latin America
MSD’s Leonardo Semprun, writing in the June 2025 edition of DIA’s Global Forum magazine, reflects on some of the key lessons from the Latin America Town Hall at DIA Europe…
Address: Escalada 1454, Buenos Aires (C1407LED),Argentina
Tel: (5411) 4670-3474
Web: http://www.dromex.com.ar/index_en.php
Dromex is a company founded on the basis of commitment and business loyalty between customers and suppliers in the Argentinian market. Dromex has over 25 years of experience in supplying active principles for the pharmaceutical industry, as well as a highly qualified, proactive and efficient professional work team to offer a high-class service.
Dromex’s main business is representing manufacturers of active principles for the Argentinean pharmaceutical industry. We represent first-class companies who work under the highest quality standards, recognized worldwide.
Having its own warehouse, authorized by the ANMAT (local regulatory agency), enables Dromex to keep the raw materials with the highest demand. Dromex can therefore offer a wide range of products and services to meet all the needs of any laboratory.
Dromex has a subsidiary in Brazil, Dromex Brasil, which carries out the same type of business in that market.
Warehousing, representing manufacturers
MSD’s Leonardo Semprun, writing in the June 2025 edition of DIA’s Global Forum magazine, reflects on some of the key lessons from the Latin America Town Hall at DIA Europe…
A roundup of some of the biggest stories coming out of Latin American pharma and healthcare, including Mexico’s move to speed up the drug review process; Sanfer’s acquisition of Columbia’s…
A roundup of top stories from Latin American pharma and healthcare, including the beginning of the Mexican government’s consolidated procurement of medicines; Libbs’ new biologics plant; Novo Nordisk’s USD 142.4…
An overview of some of the biggest news from Latin American pharma, including Onconic Therapeutics’ licensing deal with Laboratorios Sanfer for 19 LatAm countries; Lupin’s orphan drug partnership with Argentina’s…
A roundup of some of the latest stories coming out of Latin American pharma and healthcare, including Merck’s new distribution centre in Brazil; the region’s record dengue surge; Roemmers Laboratory’s…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Mariana Abdala of Crystal Research outlines the vast room for improvement in Latin America’s clinical trial output, the region’s…
Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC…
Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful…
While Bayer’s recent history has been dominated by the controversial Monsanto acquisition, the German firm will be hoping for a more straightforward next few years with a new leadership team…
Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful…
Axios International has been designing and implementing access to healthcare solutions in collaboration with the pharmaceutical industry and other healthcare players across Latin America (LatAm), Europe, the Middle East, Africa,…
Maria Gabriela Pittis, Head of SAM (South Cone, Andean Region, Mexico & Central America and Caribbean) at Takeda, outlines the company’s significant presence in the cluster, its double digit growth…
See our Cookie Privacy Policy Here
